Skip to content
DraconiticResearch
Search Sources API
197,788 studies31 sourcesUpdated 32 min ago
Peer-reviewedCC BY-NC-ND 4.0Scientific Reports

IL-6R blockade with tocilizumab disrupts pericyte– and tumor cell–driven IL-6/STAT3 signaling, enhancing docetaxel efficacy in ER+ breast cancer

  • Róża K. Przanowska
  • Jacky Gomez-Villa
  • Victoria J. Liu
  • Natalia Antonides-Jensen
  • Lavanya Visvabharathy
  • John C. Alverdy
  • Sonia L. Hernandez
  • Samantha S. Yee
Open at sourcePDFDOICite

Related

  1. Repeated Neuromuscular Electrical Stimulation Protocol Disrupts Muscle-to-Brain Signaling in Rats
    J. Wirtz, Y. Wang, R. Chaney +9
    bioRxivPreprintCC BY-NC-NDFull textPhysiologybioRxiv
  2. Tumor Treating Fields Enhance Temozolomide-Associated Growth Suppression in Glioblastoma Cells and Patient-Derived Organoids Through Cell-Cycle Blockade, Apoptosis, and SMAD-Associated Signaling.
    Haiping Zhu, Yingbo Hou, Xuetao Li +14
    CNS neuroscience & therapeuticsPeer-reviewedCC BYFull textHuman geneticsEurope PMC
  3. PLPP1 inhibits Wnt/β-catenin signaling via enhancing Caveolin-1/β-catenin interaction and is negatively regulated by c-Myc in osteosarcoma
    Jiangbo Nie, Yang Zhou, Xinsheng Xie +7
    Journal of orthopaedic translationPeer-reviewedCC BY-NC-NDFull textGeneral medicineEurope PMC
  4. ATR inhibition potentiates immunotherapy efficacy via TBK1-NFκB signaling and autophagy blockade in non-small cell lung cancer.
    Guo Li, Lingping Kong, Shasha Guan +4
    Cancer immunology, immunotherapy : CIIPeer-reviewedCC BY-NC-NDFull textOncologyEurope PMCPMC
  5. Dual CD73/A2AR blockade modulates the neurotoxic astrocyte phenotype without disrupting core inflammatory signaling
    Katarina Mihajlovic, Milorad Dragic, Marija Adzic Bukvic +7
    Frontiers in PharmacologyPeer-reviewedCC BYFull text1 citedPhysiologyHAL

Cite

BibTeXRIS
BibTeX
@article{przanowska2026il6r,
  title = {{IL-6R blockade with tocilizumab disrupts pericyte– and tumor cell–driven IL-6/STAT3 signaling, enhancing docetaxel efficacy in ER+ breast cancer}},
  author = {Róża K. Przanowska and Jacky Gomez-Villa and Victoria J. Liu and Natalia Antonides-Jensen and Lavanya Visvabharathy and John C. Alverdy and Sonia L. Hernandez and Samantha S. Yee},
  journal = {Scientific Reports},
  year = {2026},
  month = oct,
  doi = {10.1038/s41598-026-75881-7},
  url = {https://www.nature.com/articles/s41598-026-75881-7},
  note = {CC BY-NC-ND 4.0},
}
RIS
TY  - JOUR
TI  - IL-6R blockade with tocilizumab disrupts pericyte– and tumor cell–driven IL-6/STAT3 signaling, enhancing docetaxel efficacy in ER+ breast cancer
AU  - Róża K. Przanowska
AU  - Jacky Gomez-Villa
AU  - Victoria J. Liu
AU  - Natalia Antonides-Jensen
AU  - Lavanya Visvabharathy
AU  - John C. Alverdy
AU  - Sonia L. Hernandez
AU  - Samantha S. Yee
PY  - 2026
DA  - 2026/10/16
JO  - Scientific Reports
DO  - 10.1038/s41598-026-75881-7
UR  - https://www.nature.com/articles/s41598-026-75881-7
SN  - 2045-2322
ER  -